Try our mobile app
INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021, to be held virtually September 16-21. Data will also be presented on Innovent's sintilimab, for which Lilly has an exclusive license for geographies outside of China.
Details on poster presentations for Verzenio, Retevmo and CYRAMZA are shared below.
Medicine | Abstract Title | Presentation Details |
Verzenio (abemaciclib) | Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status | Abstract #: 153P Poster available: September 16 at 08:30 CEST |
Verzenio (abemaciclib) | Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2 | Abstract #: 241P Poster available: September 16 at 08:30 CEST |
Retevmo (selpercatinib) | Real-world study of REarranged during Transfection [RET] testing in patients [pts] with medullary thyroid cancer [MTC] in Europe [EU5] | Abstract #: 1751P Poster available: September 16 at 08:30 CEST |
Retevmo (selpercatinib) | Characteristics and treatment [tx] patterns in patients [pts] with medullary thyroid cancer [MTC] with and without REarranged during Transfection [RET] mutations in Europe | Abstract #: 1752P Poster available: September 16 at 08:30 CEST |
Retevmo (selpercatinib) | REarranged during Transfection [RET] gene fusion testing patterns for patients [pts] with papillary thyroid cancer [PTC] across five European countries | Abstract #: 1753P Poster available: September 16 at 08:30 CEST |
CYRAMZA (ramucirumab) | RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): Association between TP53 status and clinical outcome | Abstract #: 1209P Poster available: September 16 at 08:30 CEST |
Details on presentations for sintilimab are shared below. | ||
sintilimab | Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study | Abstract #: LBA52 Mini-Oral Presentation: September 17, 17:30 – 17:35 CEST |
sintilimab | Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study | Abstract #: LBA53 Mini-Oral Presentation: September 17, 17:35 – 17:40 CEST |
Notes to Editors
About Verzenio® (abemaciclib)Verzenio (abemaciclib) is an inhibitor of cyclin-dependent kinases (CDK)4 & 6, which are activated by binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4 & 6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation.
In vitro, continuous exposure to Verzenio inhibited Rb phosphorylation and blocked progression from G1 to S phase of the cell cycle, resulting in senescence and apoptosis (cell death). Preclinically, Verzenio dosed daily without interruption resulted in reduction of tumor size. Inhibiting CDK4 & 6 in healthy cells can result in side effects, some of which may be serious. Clinical evidence also suggests that Verzenio crosses the blood-brain barrier. In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.
Verzenio is Lilly's first solid oral dosage form to be made using a faster, more efficient process known as continuous manufacturing. Continuous manufacturing is a new and advanced type of manufacturing within the pharmaceutical industry, and Lilly is one of the first companies to use this technology.
INDICATION FOR VERZENIOVerzenio is indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer:
About Retevmo® (selpercatinib)Retevmo (selpercatinib, capsules 40mg, 80mg; formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a selective and potent RET kinase inhibitor. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. RET-driver alterations are predominantly mutually exclusive from other oncogenic drivers. Retevmo is an U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (
